Search results
Results from the WOW.Com Content Network
Eli Lilly (NYSE: LLY) stock was the picture of health on Friday. Shares of the massive American pharmaceutical company rose by more than 2% on the day, thanks largely to news from a rival. Eli ...
The S&P 500 rose 0.1% as three out of every four stocks in the index climbed. The Dow Jones Industrial Average added 221 points, or 0.5%, and the Nasdaq composite slipped 0.2%.
The good news for investors is that for 2025, overall guidance is looking strong. Lilly is projecting between $58 billion and $61 billion in sales, which is mostly higher than the $58.4 billion ...
J.P. Morgan Research forecasts that the GLP-1 market will exceed $100 billion by 2030, and total GLP-1 users may number around 9 percent of the overall U.S. population. Other analysts are even ...
The excitement surrounding the weight loss market has fueled a stock-buying frenzy, propelling Lilly to a market capitalization of roughly $720 billion -- making it the most valuable ...
Price Action: LLY stock is down by 0.14% at $802.42 at the last check Tuesday. Read Next: United Natural Foods Beats Q1 Estimates On Positive Volume Trends, Lifts FY25 Guidance
LLY data by YCharts. Considering that management is still calling for another year of 32% revenue growth in 2025, I'm hard-pressed to explain why investors are panic-selling the stock.
However, Eli Lily is a fast-growing company, with a price/earnings-to-growth ratio (PEG ratio) of only 0.5. PEGs under 1 are usually considered undervalued, so on that basis, the stock is inexpensive.